30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q14 Revenue: K2M

$42.3MM, +20% (U.S. $29.8MM, +15%; ex-U.S. $12.5MM, +32%)

  • U.S. Complex Spine $10.1MM, +9%
  • U.S. Minimally Invasive $6.4MM, +14%
  • U.S. Degenerative $13.0MM, +21%


  • Growth driven primarily by U.S. expansion of customer base, changes in product mix driven by degenerative portfolio
  • Ex-U.S. growth reflects higher sales of MESA in certain markets, penetration of direct and independent distributor markets
  • Received FDA 510(k) clearance for CAYMAN Minimally Invasive, for use with RAVINE Lateral Access
  • Completed IPO, net proceeds ~$120MM